sulfonyldimethaneWhat was measured
Measured, with no finding
244 endpoints
Show what was measuredHide what was measured
performing activities of daily living, SF-36
increases, improvement compared to placebo
Not recorded as a finding: no outcome node for the SF-36 activities-of-daily-living domain
MSM also produced improvement in performing activities of daily living when compared to placebo on the SF-36 evaluation (P<0.05).
PMID 16309928 · one of two readings recorded this
performing activities of daily living
increases, p = 0.05
MSM also produced improvement in performing activities of daily living when compared to placebo on the SF-36 evaluation (P<0.05)
PMID 16309928 · one of two readings recorded this
SF-36 activities of daily living item
increases
Not recorded as a finding: no outcome node for the SF-36 activities-of-daily-living item; the ADL node requires Barthel or Katz
MSM also produced improvement in performing activities of daily living when compared to placebo on the SF-36 evaluation (P<0.05).
PMID 16309928 · one of two readings recorded this
WOMAC aggregated total symptoms score
no effect
No notable changes were found in WOMAC stiffness and aggregated total symptoms scores
PMID 16309928 · one of two readings recorded this
WOMAC pain
decreases, p = 0.05
Compared to placebo, MSM produced significant decreases in WOMAC pain and physical function impairment (P<0.05)
PMID 16309928 · one of two readings recorded this
WOMAC physical function impairment
decreases, p = 0.05
Compared to placebo, MSM produced significant decreases in WOMAC pain and physical function impairment (P<0.05)
PMID 16309928 · one of two readings recorded this
WOMAC stiffness subscale and aggregated total symptoms score
no effect
Not recorded as a finding: agentless sentence names no compound or comparator
No notable changes were found in WOMAC stiffness and aggregated total symptoms scores.
PMID 16309928 · one of two readings recorded this
WOMAC stiffness subscale, visual analogue scale
no notable changes
Not recorded as a finding: the only sentence is agentless and names neither MSM nor the comparator
No notable changes were found in WOMAC stiffness and aggregated total symptoms scores.
PMID 16309928 · one of two readings recorded this
WOMAC stiffness
no effect
No notable changes were found in WOMAC stiffness and aggregated total symptoms scores
PMID 16309928 · one of two readings recorded this
WOMAC physical function subscale
decreases, p = 0.04, n = 50
Function | 0.85 | 0.04*
PMID 21708034 · one of two readings recorded this
WOMAC physical function subscale
decreases, p = 0.01, n = 50
Function | 36.6 ± 23.7 | 33.1 ± 23.1 | -7.7 ± 19.3 [-15.8, 0.3] | 46.2 ± 25.1 | 54.3 ± 21.1 | 6.9 ± 17.0 [0.1, 13.9] | 14.6 [4.3, 25.0] | 0.51 | 0.01*
PMID 21708034 · one of two readings recorded this
WOMAC pain subscale
no effect, p = 0.08, n = 50
Pain | 0.43 | 0.08
PMID 21708034 · one of two readings recorded this
WOMAC pain subscale
decreases, p = 0.05, n = 50
Pain | 35.5 ± 26.1 | 34.0 ± 24.5 | -9.0 ± 24.0 [-18.9, 0.9] | 47.1 ± 26.6 | 49.4 ± 20.8 | 3.5 ± 19.3 [-4.5, 11.5] | 12.4 [0.0, 24.8] | 0.20 | 0.05*
PMID 21708034 · one of two readings recorded this
WOMAC stiffness subscale
no effect, p = 0.08, n = 50
Stiffness | 0.23 | 0.08
PMID 21708034 · one of two readings recorded this
WOMAC stiffness subscale
decreases, p = 0.01, n = 50
Stiffness | 39.2 ± 31.0 | 36.0 ± 26.2 | -11.7 ± 30.7 [-24.3, 1.0] | 52.9 ± 30.4 | 58.5 ± 24.2 | 15.5 ± 35.8 [0.7, 30.3] | 27.2 [8.2, 46.2] | 0.03* | 0.01*
PMID 21708034 · one of two readings recorded this
Aggregated Locomotor Function (ALF) score
no effect, p = 0.09, n = 50
ALF | 0.31 | 0.09
PMID 21708034 · one of two readings recorded this
Aggregated Locomotor Function (ALF) score
decreases, n = 50
ALF | 36.5 ± 16.6 | 36.9 ± 20.7 | -6.8 ± 10.3 [-11.0, -2.5] | 32.2 ± 10.6 | 33.9 ± 10.9 | 0.8 ± 4.9 [-1.2, 2.8] | 7.6 [2.9, 12.2] | 0.02* | 0.00*
PMID 21708034 · one of two readings recorded this
Knee Society Function Score (KSFS)
no effect, p = 0.63, n = 50
KSFS | 0.29 | 0.63
PMID 21708034 · one of two readings recorded this
Knee Society Knee Score (KSKS)
no effect, p = 0.09, n = 50
Secondary | KSKS | 0.43 | 0.09
PMID 21708034 · one of two readings recorded this
pain on a 10 cm visual analogue scale, change 0-12 weeks
difference 0.7 cm [CI -0.9, 2.4], p = 0.05
Not recorded as a finding: Interval of the between-group difference includes zero and the unadjusted p is 0.38 in Table 2 against 0.05 adjusted in Table 3; no clean direction sentence
This corresponded to a 0.7 cm [CI: -0.9, 2.4] difference between the changes in each group (p = 0.05).
PMID 21708034 · one of two readings recorded this
SF-36 score
no effect, p = 0.54, n = 50
SF-36 | 0.98 | 0.54
PMID 21708034 · one of two readings recorded this
SF-36 score
increases, p = 0.03, n = 50
SF-36 | 59.8 ± 19.7 | 62.2 ± 20.3 | 8.1 ± 21.8 [-0.8, 17.1] | 61.1 ± 16.2 | 54.5 ± 15.4 | -3.4 ± 14.6 [-9.5, 2.6] | -11.6 [-22.1, -1.0] | 0.52 | 0.03*
PMID 21708034 · one of two readings recorded this
VAS pain, 10 cm line, 12 weeks
decreases
Not recorded as a finding: the sentence names the MSM group with no comparator, and its interval (-0.9 to 2.4) straddles zero while the text calls it significant at p = 0.05
The MSM group showed a significant reduction in pain on the VAS.
PMID 21708034 · one of two readings recorded this
visual analogue scale for pain
decreases, p = 0.05, n = 50
VAS | 0.06 | 0.05*
PMID 21708034 · one of two readings recorded this
visual analogue scale for pain
no effect, p = 0.38, n = 50
VAS | 3.30 ± 2.8 | 3.61 ± 2.9 | -0.2 ± 3.2 [-1.5, 1.1] | 5.22 ± 2.9 | 5.16 ± 2.22 | 0.6 ± 2.7 [-0.6, 1.7] | 0.7 [-0.9, 2.4] | 0.18 | 0.38
PMID 21708034 · one of two readings recorded this
WOMAC aggregated total score
decreases, p = 0.03, n = 50
Total | 0.60 | 0.03*
PMID 21708034 · one of two readings recorded this
WOMAC aggregated total score
decreases, n = 50
Total | 36.6 ± 23.9 | 33.3 ± 22.5 | -8.4 ± 17.8 [-15.8, -1.1] | 47.2 ± 24.5 | 53.5 ± 20.3 | 6.5 ± 17.0 [0.5, 13.5] | 15.0 [5.1, 24.9] | 0.26 | 0.00*
PMID 21708034 · one of two readings recorded this
WOMAC aggregated total symptoms score, change 0-12 weeks
decreases, difference 15.0 mm [CI 5.1, 24.9], p = 0.03
Not recorded as a finding: No outcome node for the WOMAC total score
Total symptoms decreased by 20% (8.4 mm [CI: 1.1, 15.8]) in the MSM group and increased by 14% (6.6 mm [CI: 0.5, 13.5]) in the placebo group, corresponding to a difference of 15.0 mm [CI: 5.1, 24.9] between groups (p = 0.03).
PMID 21708034 · one of two readings recorded this
WOMAC pain subscale, 0-100 mm, 12 weeks
no effect
Not recorded as a finding: sentence says no significant difference between 'treatment groups' without naming MSM, and that label is not defined in Methods; the numeric sentence gives a direction with p = 0.08 and no absence stated in words
No significant difference was found between treatment groups over time in the WOMAC pain or stiffness subscales.
PMID 21708034 · one of two readings recorded this
WOMAC pain subscale, change 0-12 weeks
no effect
Not recorded as a finding: Quote labels the arms 'treatment groups' with no Methods clause defining that label, and the unadjusted table (p = 0.05) and adjusted table (p = 0.08) disagree
No significant difference was found between treatment groups over time in the WOMAC pain or stiffness subscales.
PMID 21708034 · one of two readings recorded this
WOMAC stiffness subscale, 0-100 mm, 12 weeks
no effect
Not recorded as a finding: same sentence as pain; compound not named and arm label 'treatment groups' undefined; unadjusted table p = 0.01 and adjusted p = 0.08 disagree in direction of significance
No significant difference was found between treatment groups over time in the WOMAC pain or stiffness subscales.
PMID 21708034 · one of two readings recorded this
GSH/GSSG ratio
increases
The plasma level of GSH and the ratio of GSH/GSSG were significantly higher in the MSM supplemented group
PMID 21899544 · one of two readings recorded this
malondialdehyde (MDA) after exercise
decreases
MSM supplementation maintained PC, MDA and GSSG at lower levels after exercise than the placebo
PMID 21899544 · one of two readings recorded this
oxidized glutathione (GSSG) after exercise
decreases
MSM supplementation maintained PC, MDA and GSSG at lower levels after exercise than the placebo
PMID 21899544 · one of two readings recorded this
plasma oxidized glutathione (GSSG) after exercise
decreases, maintained at lower levels than placebo
Not recorded as a finding: no outcome node for oxidized glutathione
MSM supplementation maintained PC, MDA and GSSG at lower levels after exercise than the placebo.
PMID 21899544 · one of two readings recorded this
plasma reduced glutathione (GSH), and GSH/GSSG ratio
increases, significantly higher in the MSM supplemented group
Not recorded as a finding: the only sentence says higher in the MSM supplemented group and names no comparator, so it is not self-supporting against placebo
The plasma level of GSH and the ratio of GSH/GSSG were significantly higher in the MSM supplemented group.
PMID 21899544 · both readings recorded this
protein carbonyl (PC) after exercise
decreases
MSM supplementation maintained PC, MDA and GSSG at lower levels after exercise than the placebo
PMID 21899544 · one of two readings recorded this
reduced glutathione (GSH)
increases
The plasma level of GSH and the ratio of GSH/GSSG were significantly higher in the MSM supplemented group
PMID 21899544 · one of two readings recorded this
serum protein carbonyl and plasma oxidized glutathione (GSSG) after exercise
decreases
Not recorded as a finding: no outcome node for protein carbonyls or GSSG
MSM supplementation maintained PC, MDA and GSSG at lower levels after exercise than the placebo.
PMID 21899544 · one of two readings recorded this
serum protein carbonyl (PC) after exercise
decreases, maintained at lower levels than placebo
Not recorded as a finding: no outcome node for protein carbonyls
MSM supplementation maintained PC, MDA and GSSG at lower levels after exercise than the placebo.
PMID 21899544 · one of two readings recorded this
bilirubin
decreases, p = 0.002
CK and bilirubin significantly increased in P group 24 h after exercise compared to M group (P=0.041 and P=0.002, respectively)
PMID 22525653 · one of two readings recorded this
creatine kinase (CK)
decreases, p = 0.041
CK and bilirubin significantly increased in P group 24 h after exercise compared to M group (P=0.041 and P=0.002, respectively)
PMID 22525653 · one of two readings recorded this
serum bilirubin after a 14 km run
decreases, P=0.002 at 24 h, placebo higher than MSM, p = 0.002, n = 18
Not recorded as a finding: no outcome node for bilirubin
CK and bilirubin significantly increased in P group 24 h after exercise compared to M group (P=0.041 and P=0.002, respectively).
PMID 22525653 · both readings recorded this
total antioxidant capacity (TAC)
increases, p = 0.014
TAC showed significant increase in M group 2 and 24 h after exercise compared to P group (P=0.014 and P=0.033, respectively)
PMID 22525653 · one of two readings recorded this
total antioxidant capacity (TAC)
increases, p = 0.033
TAC showed significant increase in M group 2 and 24 h after exercise compared to P group (P=0.014 and P=0.033, respectively)
PMID 22525653 · one of two readings recorded this
total antioxidant capacity (TAC)
increases, p = 0.05
TAC increased immediately post, 30 min, 2 and 24 h after exercise just in M group (P<0.05)
PMID 22525653 · one of two readings recorded this
serum uric acid
decreases, p = 0.039, n = 16
The post hoc analysis showed a significant difference between placebo and MSM groups at post-exercise time points (p = 0.039)
PMID 24523764 · one of two readings recorded this
plasma GSH, treatment by time interaction
no effect, p = 0.64, n = 16
The results of two factor ANOVA did not reveal any significant treatment effect (p = 0.828), time effect (p = 0.062), or treatment by time interaction (p = 0.64)
PMID 24523764 · one of two readings recorded this
plasma GSH, treatment effect
no effect, p = 0.828, n = 16
The results of two factor ANOVA did not reveal any significant treatment effect (p = 0.828), time effect (p = 0.062), or treatment by time interaction (p = 0.64)
PMID 24523764 · one of two readings recorded this
plasma reduced glutathione (GSH)
no effect, p = 0.828
Not recorded as a finding: two-factor ANOVA sentence is agentless and names neither MSM nor placebo
The results of two factor ANOVA did not reveal any significant treatment effect (p = 0.828), time effect (p = 0.062), or treatment by time interaction (p = 0.64).
PMID 24523764 · both readings recorded this
plasma total antioxidant capacity, 24 h after exercise
p = 0.017
Not recorded as a finding: Quote has no direction word
A significant difference was detected at 24 h values (p = 0.017) when comparing placebo and MSM groups.
PMID 24523764 · one of two readings recorded this
plasma total antioxidant capacity at 24 h after exercise
p = 0.017
Not recorded as a finding: between-group sentence states a significant difference with no direction word
A significant difference was detected at 24 h values (p = 0.017) when comparing placebo and MSM groups.
PMID 24523764 · one of two readings recorded this
plasma total antioxidant capacity
increases, p = 0.017, n = 16
A significant difference was detected at 24 h values (p = 0.017) when comparing placebo and MSM groups
PMID 24523764 · one of two readings recorded this
plasma vitamin E
decreases, p = 0.043, n = 16
A significant increase was measured for vitamin E level in placebo group when comparing with MSM at 2 h after exercise (p = 0.043)
PMID 24523764 · one of two readings recorded this
serum malondialdehyde at pre-exercise and 2 h after exercise
decreases, p = 0.034
Not recorded as a finding: sentence names the groups only as P and M and states no direction; the direction sentence names no comparator
Post hoc analysis showed significant difference on MDA level at pre-exercise (p = 0.036) and 2 h after exercise (p = 0.034) when comparing P and M groups (Table 3).
PMID 24523764 · one of two readings recorded this
serum malondialdehyde (MDA), pre-exercise and 2 h after exercise
p = 0.034
Not recorded as a finding: Sentences give a significant difference with no direction word, or state the decrease without naming the comparator
Post hoc analysis showed significant difference on MDA level at pre-exercise (p = 0.036) and 2 h after exercise (p = 0.034) when comparing P and M groups (Table 3).
PMID 24523764 · one of two readings recorded this
serum MDA
decreases, p = 0.036, n = 16
Post hoc analysis showed significant difference on MDA level at pre-exercise (p = 0.036) and 2 h after exercise (p = 0.034) when comparing P and M groups
PMID 24523764 · one of two readings recorded this
serum MDA
decreases, p = 0.034, n = 16
Post hoc analysis showed significant difference on MDA level at pre-exercise (p = 0.036) and 2 h after exercise (p = 0.034) when comparing P and M groups
PMID 24523764 · one of two readings recorded this
serum protein carbonyl content, 2 h and 24 h after exercise
decreases, p = 0.012
Not recorded as a finding: No outcome node for protein carbonyls
Again, post hoc analysis showed significant differences on PC level at 2 and 24 h after exercise (p < 0.001 and p = 0.012, respectively) comparing placebo and MSM groups.
PMID 24523764 · one of two readings recorded this
serum protein carbonyl content
decreases, p = 0.012
Not recorded as a finding: no outcome node for protein carbonyl
Again, post hoc analysis showed significant differences on PC level at 2 and 24 h after exercise (p < 0.001 and p = 0.012, respectively) comparing placebo and MSM groups.
PMID 24523764 · one of two readings recorded this
serum protein carbonyl
decreases, n = 16
Again, post hoc analysis showed significant differences on PC level at 2 and 24 h after exercise (p < 0.001 and p = 0.012, respectively) comparing placebo and MSM groups
PMID 24523764 · one of two readings recorded this
serum protein carbonyl
decreases, p = 0.012, n = 16
Again, post hoc analysis showed significant differences on PC level at 2 and 24 h after exercise (p < 0.001 and p = 0.012, respectively) comparing placebo and MSM groups
PMID 24523764 · one of two readings recorded this
serum total bilirubin, post-exercise
decreases, p = 0.017
Not recorded as a finding: No outcome node for bilirubin
A significant difference was also detected at post-exercise values (p = 0.017) when comparing placebo and MSM group, showing a low level of serum bilirubin in MSM group.
PMID 24523764 · one of two readings recorded this
serum total bilirubin, post-exercise
decreases, p = 0.017, n = 16
A significant difference was also detected at post-exercise values (p = 0.017) when comparing placebo and MSM group, showing a low level of serum bilirubin in MSM group
PMID 24523764 · one of two readings recorded this
serum total bilirubin, treatment main effect
no effect, p = 0.198, n = 16
There was no significant treatment main effect (p = 0.198) or treatment by time interaction (p = 0.190), but a significant time effect (p = 0.005) was detected
PMID 24523764 · one of two readings recorded this
improvement rate, difficulty getting up from bed (self-reported)
increases, n = 99
5 | Difficulty getting up from bed | 34.7 | 6.0 | 12.639 | 0.000
PMID 26199577 · one of two readings recorded this
improvement rate, difficulty going down stairs (self-reported)
increases, n = 99
6 | Difficulty going down stairs | 77.6 | 14.0 | 40.313 | 0.000
PMID 26199577 · one of two readings recorded this
improvement rate, difficulty walking (self-reported)
increases, n = 99
4 | Difficulty walking | 51.0 | 8.0 | 22.113 | 0.000
PMID 26199577 · one of two readings recorded this
improvement rate, heat (joint examination)
no effect, p = 0.197, n = 99
9 | Heat | 10.2 | 2.0 | 1.662 | 0.197
PMID 26199577 · one of two readings recorded this
improvement rate, joint movement disorder (joint examination)
increases, n = 99
11 | Joint movement disorder | 61.2 | 14.0 | 23.580 | 0.000
PMID 26199577 · one of two readings recorded this
improvement rate, joint pain (self-reported)
increases, n = 99
1 | Joint pain | 77.6 | 16.0 | 37.691 | 0.000
PMID 26199577 · one of two readings recorded this
improvement rate, joint stiffness (self-reported)
increases, p = 0.024, n = 99
2 | Joint stiffness | 30.6 | 12.0 | 5.130 | 0.024
PMID 26199577 · one of two readings recorded this
improvement rate, joint swelling (self-reported)
increases, n = 99
3 | Joint swelling | 22.4 | 0.0 | 12.628 | 0.000
PMID 26199577 · one of two readings recorded this
improvement rate, pain (joint examination)
increases, n = 99
10 | Pain | 75.5 | 16.0 | 35.349 | 0.000
PMID 26199577 · one of two readings recorded this
improvement rate, skin redness (joint examination)
no effect, p = 0.121, n = 99
7 | Skin redness | 8.2 | 0.0 | 2.409 | 0.121
PMID 26199577 · one of two readings recorded this
improvement rate, swelling (joint examination)
increases, n = 99
8 | Swelling | 28.6 | 0.0 | 16.639 | 0.000
PMID 26199577 · one of two readings recorded this
joint examination average score after intervention
no effect, p = 0.092, n = 99
Average Score | 1.78 ± 0.56 | 1.96 ± 0.46 | -1.700 | 0.092
PMID 26199577 · one of two readings recorded this
joint examination heat after intervention
no effect, p = 0.324, n = 99
Heat | 1.33 ± 0.75 | 1.20 ± 0.50 | 0.992 a | 0.324
PMID 26199577 · one of two readings recorded this
joint examination joint movement disorder after intervention
decreases, p = 0.004, n = 99
Joint movement disorder | 2.37 ± 0.70 | 2.84 ± 0.87 | -2.987 | 0.004
PMID 26199577 · one of two readings recorded this
joint examination pain after intervention
decreases, p = 0.002, n = 99
Pain | 2.75 ± 0.76 | 3.08 ± 0.83 | -3.173 | 0.002
PMID 26199577 · one of two readings recorded this
joint examination skin redness after intervention
increases, p = 0.046, n = 99
Skin redness | 1.16 ± 0.47 | 1.02 ± 0.14 | 2.037 a | 0.046
PMID 26199577 · one of two readings recorded this
joint examination swelling after intervention
no effect, p = 0.32, n = 99
Swelling | 1.49 ± 0.82 | 1.66 ± 0.87 | -1.001 | 0.320
PMID 26199577 · one of two readings recorded this
physician- and self-rated joint pain score (1 to 5) after 12 weeks, Mega MSM versus placebo
decreases, joint pain 2.51 vs 3.04, p = 0.003, n = 99
Not recorded as a finding: the intervention held more than the compound
After the intervention, the score of joint pain in the Mega MSM group was 2.51 ± 0.82, lower than the score of 3.04 ± 0.93 in the placebo group (p=0.003).
PMID 26199577 · one of two readings recorded this
self-reported difficulty getting up from bed after intervention
no effect, p = 0.145, n = 99
Difficulty getting up from bed | 1.76 ± 0.88 | 2.02 ± 0.92 | -1.469 | 0.145
PMID 26199577 · one of two readings recorded this
self-reported difficulty going down stairs after intervention
no effect, p = 0.14, n = 99
Difficulty going down stairs | 2.37 ± 0.76 | 2.64 ± 1.05 | -1.490 a | 0.140
PMID 26199577 · one of two readings recorded this
self-reported difficulty walking after intervention
no effect, p = 0.454, n = 99
Difficulty walking | 1.98 ± 0.80 | 2.12 ± 1.04 | -0.751 a | 0.454
PMID 26199577 · one of two readings recorded this
self-reported joint pain after intervention
decreases, p = 0.003, n = 99
Joint pain | 2.51 ± 0.82 | 3.04 ± 0.93 | -3.014 | 0.003
PMID 26199577 · one of two readings recorded this
self-reported joint pain score (physician-assigned 1 to 5) after 12 weeks of Mega MSM capsules versus placebo in adults over 50 with joint degeneration; also SF-36 and joint examination scores
decreases, joint pain score 2.51 vs 3.04, p = 0.003, n = 99
Not recorded as a finding: the intervention held more than the compound
After the intervention, the score of joint pain in the Mega MSM group was 2.51 ± 0.82, lower than the score of 3.04 ± 0.93 in the placebo group (p=0.003).
PMID 26199577 · one of two readings recorded this
self-reported joint stiffness after intervention
no effect, p = 0.087, n = 99
Joint stiffness | 2.00 ± 0.87 | 2.34 ± 1.08 | -1.729a | 0.087
PMID 26199577 · one of two readings recorded this
self-reported joint swelling after intervention
no effect, p = 0.199, n = 99
Joint swelling | 1.51 ± 0.82 | 1.74 ± 0.94 | -1.293 | 0.199
PMID 26199577 · one of two readings recorded this
self-reported joint symptoms average score after intervention
decreases, p = 0.036, n = 99
Average Score | 2.02 ± 0.70 | 2.32 ± 0.68 | -2.130 | 0.036
PMID 26199577 · one of two readings recorded this
SF-36 bodily pain (BP) after intervention
no effect, p = 0.053, n = 99
BP | 70.00 ± 11.37 | 65.00 ± 13.89 | 1.962 a | 0.053
PMID 26199577 · one of two readings recorded this
SF-36 general health (GH) after intervention
no effect, p = 0.542, n = 99
GH | 58.88 ± 21.66 | 56.40 ± 18.55 | 0.612 | 0.542
PMID 26199577 · one of two readings recorded this
SF-36 health transition (HT) after intervention
no effect, p = 0.965, n = 99
HT | 44.39 ± 13.76 | 44.50 ± 11.62 | -0.044 | 0.965
PMID 26199577 · one of two readings recorded this
SF-36 mental composite score (MCS) after intervention
increases, p = 0.049, n = 99
MCS | 324.31 ± 45.30 | 304.01 ± 55.50 | 1.991 | 0.049
PMID 26199577 · one of two readings recorded this
SF-36 mental health (MH) after intervention
increases, n = 99
MH | 84.33 ± 8.83 | 74.88 ± 13.55 | 4.119 a | 0.000
PMID 26199577 · one of two readings recorded this
SF-36 physical composite score (PCS) after intervention
no effect, p = 0.175, n = 99
PCS | 255.00 ± 77.43 | 232.50 ± 86.33 | 1.366 a | 0.175
PMID 26199577 · one of two readings recorded this
SF-36 physiological functioning (PF) after intervention
increases, p = 0.005, n = 99
PF | 72.04 ± 17.11 | 61.60 ± 18.99 | 2.872 | 0.005
PMID 26199577 · one of two readings recorded this
SF-36 role-emotional (RE) after intervention
no effect, p = 0.128, n = 99
RE | 95.24 ± 18.00 | 87.33 ± 31.51 | 1.536 a | 0.128
PMID 26199577 · one of two readings recorded this
SF-36 role-physical (RP) after intervention
no effect, p = 0.619, n = 99
RP | 54.08 ± 40.94 | 49.50 ± 50.12 | 0.499 a | 0.619
PMID 26199577 · one of two readings recorded this
SF-36 social functioning (SF) after intervention
no effect, p = 0.831, n = 99
SF | 71.17 ± 20.12 | 72.00 ± 18.31 | -0.214 | 0.831
PMID 26199577 · one of two readings recorded this
SF-36 total score after intervention
no effect, p = 0.107, n = 99
Total score | 623.70 ± 122.22 | 581.01 ± 138.49 | 1.625 | 0.107
PMID 26199577 · one of two readings recorded this
SF-36 vitality (VT) after intervention
no effect, p = 0.29, n = 99
VT | 73.57 ± 18.65 | 69.80 ± 16.60 | 1.063 | 0.290
PMID 26199577 · one of two readings recorded this
MDA
no effect, n = 22
ΔGroup | 3.7 (−3.2–10.5) | 0.9 (−4.6–6.4) | −1.1 (−4.5–2.4) | −2.8 (−6.9–1.4)
PMID 28736511 · one of two readings recorded this
MDA
no effect, n = 22
ΔGroup | 3.7 (−3.2–10.5) | 0.9 (−4.6–6.4) | −1.1 (−4.5–2.4) | −2.8 (−6.9–1.4)
PMID 28736511 · one of two readings recorded this
MDA
no effect, n = 22
ΔGroup | 3.7 (−3.2–10.5) | 0.9 (−4.6–6.4) | −1.1 (−4.5–2.4) | −2.8 (−6.9–1.4)
PMID 28736511 · one of two readings recorded this
MDA
no effect, n = 22
ΔGroup | 3.7 (−3.2–10.5) | 0.9 (−4.6–6.4) | −1.1 (−4.5–2.4) | −2.8 (−6.9–1.4)
PMID 28736511 · one of two readings recorded this
8-OHdG
no effect, n = 22
ΔGroup | 0.54 (−0.84–1.92) | 0.94 (−0.74–2.61) | 1.04 (−0.43–2.51) | 1.27 (−0.17–2.71)
PMID 28736511 · one of two readings recorded this
8-OHdG
no effect, n = 22
ΔGroup | 0.54 (−0.84–1.92) | 0.94 (−0.74–2.61) | 1.04 (−0.43–2.51) | 1.27 (−0.17–2.71)
PMID 28736511 · one of two readings recorded this
8-OHdG
no effect, n = 22
ΔGroup | 0.54 (−0.84–1.92) | 0.94 (−0.74–2.61) | 1.04 (−0.43–2.51) | 1.27 (−0.17–2.71)
PMID 28736511 · one of two readings recorded this
8-OHdG
no effect, n = 22
ΔGroup | 0.54 (−0.84–1.92) | 0.94 (−0.74–2.61) | 1.04 (−0.43–2.51) | 1.27 (−0.17–2.71)
PMID 28736511 · one of two readings recorded this
joint pain
no effect, n = 21
ΔGroup | −8.9 (−29.1–11.3) | −9.1 (−33.0–14.7) | −10.7 a (−32.7–11.2) | −3.0 (−27.8–21.7)
PMID 28736511 · one of two readings recorded this
joint pain
no effect, n = 21
ΔGroup | −8.9 (−29.1–11.3) | −9.1 (−33.0–14.7) | −10.7 a (−32.7–11.2) | −3.0 (−27.8–21.7)
PMID 28736511 · one of two readings recorded this
joint pain
no effect, n = 21
ΔGroup | −8.9 (−29.1–11.3) | −9.1 (−33.0–14.7) | −10.7 a (−32.7–11.2) | −3.0 (−27.8–21.7)
PMID 28736511 · one of two readings recorded this
joint pain
no effect, n = 21
ΔGroup | −8.9 (−29.1–11.3) | −9.1 (−33.0–14.7) | −10.7 a (−32.7–11.2) | −3.0 (−27.8–21.7)
PMID 28736511 · one of two readings recorded this
lactate dehydrogenase
no effect, n = 22
ΔGroup | −12.2 (−47.8–23.4) | −8.3 (−49.5–32.9) | 5.2 (−21.5–31.9) | 6.0 (−22.0–33.9)
PMID 28736511 · one of two readings recorded this
lactate dehydrogenase
no effect, n = 22
ΔGroup | −12.2 (−47.8–23.4) | −8.3 (−49.5–32.9) | 5.2 (−21.5–31.9) | 6.0 (−22.0–33.9)
PMID 28736511 · one of two readings recorded this
lactate dehydrogenase
no effect, n = 22
ΔGroup | −12.2 (−47.8–23.4) | −8.3 (−49.5–32.9) | 5.2 (−21.5–31.9) | 6.0 (−22.0–33.9)
PMID 28736511 · one of two readings recorded this
lactate dehydrogenase
no effect, n = 22
ΔGroup | −12.2 (−47.8–23.4) | −8.3 (−49.5–32.9) | 5.2 (−21.5–31.9) | 6.0 (−22.0–33.9)
PMID 28736511 · one of two readings recorded this
log creatine kinase
no effect, n = 22
ΔGroup | 0.02 (−0.23–0.26) | 0.03 (−0.23–0.29) | 0.18 (−0.24–0.58) | 0.11 (−0.26–0.48)
PMID 28736511 · one of two readings recorded this
log creatine kinase
no effect, n = 22
ΔGroup | 0.02 (−0.23–0.26) | 0.03 (−0.23–0.29) | 0.18 (−0.24–0.58) | 0.11 (−0.26–0.48)
PMID 28736511 · one of two readings recorded this
log creatine kinase
no effect, n = 22
ΔGroup | 0.02 (−0.23–0.26) | 0.03 (−0.23–0.29) | 0.18 (−0.24–0.58) | 0.11 (−0.26–0.48)
PMID 28736511 · one of two readings recorded this
log creatine kinase
no effect, n = 22
ΔGroup | 0.02 (−0.23–0.26) | 0.03 (−0.23–0.29) | 0.18 (−0.24–0.58) | 0.11 (−0.26–0.48)
PMID 28736511 · one of two readings recorded this
muscle pain (compared to placebo, MSM lower)
decreases, p = 0.063
Compared to placebo, MSM supplementation resulted in non-significantly lower muscle pain at T1 (p = 0.063)
PMID 28736511 · one of two readings recorded this
muscle pain on a 100 mm visual analogue scale at 15 min, 90 min, 1 day and 2 days after a half-marathon, MSM versus placebo; also serum 8-OHdG, MDA, creatine kinase, LDH and joint pain
decreases, muscle pain lower with MSM at T1, p = 0.063, p = 0.063
Not recorded as a finding: a direction is stated and the estimate does not support it
Compared to placebo, MSM supplementation resulted in non-significantly lower muscle pain at T1 (p = 0.063), and lower muscle pain at T2 and T3.
PMID 28736511 · one of two readings recorded this
muscle pain
no effect, n = 21
ΔGroup | −19.8 a (−43.7–4.1) | −10.6 a (−36.3–15.2) | −10.0 a (−33.5–13.7) | −0.7 (−20.4–19.1)
PMID 28736511 · one of two readings recorded this
muscle pain
no effect, n = 21
ΔGroup | −19.8 a (−43.7–4.1) | −10.6 a (−36.3–15.2) | −10.0 a (−33.5–13.7) | −0.7 (−20.4–19.1)
PMID 28736511 · one of two readings recorded this
muscle pain
no effect, n = 21
ΔGroup | −19.8 a (−43.7–4.1) | −10.6 a (−36.3–15.2) | −10.0 a (−33.5–13.7) | −0.7 (−20.4–19.1)
PMID 28736511 · one of two readings recorded this
muscle pain
no effect, n = 21
ΔGroup | −19.8 a (−43.7–4.1) | −10.6 a (−36.3–15.2) | −10.0 a (−33.5–13.7) | −0.7 (−20.4–19.1)
PMID 28736511 · one of two readings recorded this
pain, methylsulfonylmethane versus placebo, statistically significant improvement of unclear clinical importance
decreases
Another six (undenatured type II collagen, avocado soybean unsaponifiables, methylsulfonylmethane, diacerein, glucosamine and chondroitin) revealed statistically significant improvements on pain
PMID 29018060 · one of two readings recorded this
structural improvement, chondroitin versus placebo
decreases
Chondroitin demonstrated statistically significant, but not clinically important structural improvement (effect size -0.30, -0.42 to -0.17)
PMID 29018060 · one of two readings recorded this
Knee Osteoarthritis Outcome Score (KOOS), 5 subscales
no effect, n = 180
Three grams of MSM administered daily did not provide significant improvements in the 5 KOOS subscales or the 6 POMS subscales at 30 days or 60 days
PMID 29214616 · one of two readings recorded this
Knee Osteoarthritis Outcome Score (KOOS), 5 subscales
no effect, n = 180
Three grams of MSM administered daily did not provide significant improvements in the 5 KOOS subscales or the 6 POMS subscales at 30 days or 60 days
PMID 29214616 · one of two readings recorded this
Profile of Mood States (POMS), 6 subscales
no effect, n = 180
Three grams of MSM administered daily did not provide significant improvements in the 5 KOOS subscales or the 6 POMS subscales at 30 days or 60 days
PMID 29214616 · one of two readings recorded this
Profile of Mood States (POMS), 6 subscales
no effect, n = 180
Three grams of MSM administered daily did not provide significant improvements in the 5 KOOS subscales or the 6 POMS subscales at 30 days or 60 days
PMID 29214616 · one of two readings recorded this
peak nasal inspiratory flow (PNIF) and visual analog scale nasal symptom scores after standardised allergen challenge, change from screening visit
increases, p = 0.02, n = 18
Not recorded as a finding: the result compares a group with itself, not with a control
Longitudinal comparison between V1 and V3 across all participants produced a significantly increased PNIF with low daily MSM consumption (15.78 U increase, 17.32%; P=.02; Table 1).
PMID 30497995 · one of two readings recorded this
peak nasal inspiratory flow (PNIF) and visual analog scale nasal symptom scores after standardized allergen challenge, longitudinal change from screening visit to day 14 of daily MSM
increases, PNIF 15.78 U increase, 17.32%, p = 0.02
Not recorded as a finding: the result compares a group with itself, not with a control
Longitudinal comparison between V1 and V3 across all participants produced a significantly increased PNIF with low daily MSM consumption (15.78 U increase, 17.32%; P=.02; Table 1).
PMID 30497995 · one of two readings recorded this
peak nasal inspiratory flow (PNIF), V1 to V2
no effect
We observed no significant effect on PNIF after 12 g of MSM
PMID 30497995 · one of two readings recorded this
PNIF, V1 to V3, all participants
increases, p = 0.02, n = 18
PNIF (L/min), mean (SD) | 91.1 (4.315) | 106.89 (4.817) | 17.32% |.02
PMID 30497995 · one of two readings recorded this
PNIF, V1 to V3
increases, p = 0.01
only the 3-g MSM dose resulted in a significant increase in PNIF of 42.22 L/min from V1 to V3 (45.35%; P=.01; Figure 3)
PMID 30497995 · one of two readings recorded this
VAS average nasal symptom score after allergen challenge, V1 to V2
decreases, p = 0.03
An acute dose of 12 g of MSM significantly decreased the VAS average nasal symptom score by 5.95 U from screening to baseline (22.49%; P=.03) in longitudinal comparison between V1 and V2
PMID 30497995 · one of two readings recorded this
VAS average nasal symptoms, V1 to V3, all participants
decreases, p = 0.001, n = 18
VAS score, mean (SD) | 26.47 (22.950) | 12.25 (12.00) | –53.72% |.001
PMID 30497995 · one of two readings recorded this
VAS average nasal symptoms, V1 to V3
decreases, p = 0.03
VAS scores decreased by 1152 U, 18.71 U, and 12.30 U for MSM 1 g (51.49%; P=.03), 3 g (61.65%; P=.009), and 6 g (46.11%; P=.03), respectively, from screening to V3
PMID 30497995 · one of two readings recorded this
VAS average nasal symptoms, V1 to V3
decreases, p = 0.009
VAS scores decreased by 1152 U, 18.71 U, and 12.30 U for MSM 1 g (51.49%; P=.03), 3 g (61.65%; P=.009), and 6 g (46.11%; P=.03), respectively, from screening to V3
PMID 30497995 · one of two readings recorded this
VAS average nasal symptoms, V1 to V3
decreases, p = 0.03
VAS scores decreased by 1152 U, 18.71 U, and 12.30 U for MSM 1 g (51.49%; P=.03), 3 g (61.65%; P=.009), and 6 g (46.11%; P=.03), respectively, from screening to V3
PMID 30497995 · one of two readings recorded this
VAS itching eyes, V1 to V2
no effect
The symptom of itching eyes was not significantly altered by the 12-g treatment
PMID 30497995 · one of two readings recorded this
VAS itching eyes, V1 to V3
decreases, p = 0.03
Itching eyes were significantly relieved by high doses but not the lowest dose: 3 g (13.10 U decrease, 65.48%; P=.03) and 6 g (12.48 U decrease, 50.38%; P=.03) from screening to day 14
PMID 30497995 · one of two readings recorded this
VAS itching eyes, V1 to V3
decreases, p = 0.03
Itching eyes were significantly relieved by high doses but not the lowest dose: 3 g (13.10 U decrease, 65.48%; P=.03) and 6 g (12.48 U decrease, 50.38%; P=.03) from screening to day 14
PMID 30497995 · one of two readings recorded this
VAS itching nose, V1 to V2
decreases, p = 0.001
itching nose (18.89 U decrease, 67.23%; P=.001)
PMID 30497995 · one of two readings recorded this
VAS itching nose, V1 to V3
decreases, p = 0.02
Itching nose symptoms decreased only at high doses of MSM: 3 g (20.00 U decrease, 70.59%; P=.02) and 6 g (18.84 U decrease, 52.05%; P=.02) from screening to day 14
PMID 30497995 · one of two readings recorded this
VAS itching nose, V1 to V3
decreases, p = 0.02
Itching nose symptoms decreased only at high doses of MSM: 3 g (20.00 U decrease, 70.59%; P=.02) and 6 g (18.84 U decrease, 52.05%; P=.02) from screening to day 14
PMID 30497995 · one of two readings recorded this
VAS nasal obstruction, V1 to V2
decreases, p = 0.04
nasal obstruction (8.02 U decrease, 17.88%; P=.04)
PMID 30497995 · one of two readings recorded this
VAS nasal obstruction, V1 to V3
decreases, p = 0.04
nasal obstruction for MSM 1 g (18.38 U decrease, 41.96%; P=.04), 3 g (25.86 U decrease, 49.59%; P=.009), and 6 g (17.98 U decrease, 46.62%; P=.02) from screening to day 14
PMID 30497995 · one of two readings recorded this
VAS nasal obstruction, V1 to V3
decreases, p = 0.009
nasal obstruction for MSM 1 g (18.38 U decrease, 41.96%; P=.04), 3 g (25.86 U decrease, 49.59%; P=.009), and 6 g (17.98 U decrease, 46.62%; P=.02) from screening to day 14
PMID 30497995 · one of two readings recorded this
VAS nasal obstruction, V1 to V3
decreases, p = 0.02
nasal obstruction for MSM 1 g (18.38 U decrease, 41.96%; P=.04), 3 g (25.86 U decrease, 49.59%; P=.009), and 6 g (17.98 U decrease, 46.62%; P=.02) from screening to day 14
PMID 30497995 · one of two readings recorded this
VAS rhinorrhea, V1 to V2
decreases, p = 0.004
rhinorrhea (10.08 U decrease, 34.99%; P=.004)
PMID 30497995 · one of two readings recorded this
VAS rhinorrhea, V1 to V3
decreases, p = 0.03
Rhinorrhea symptoms were similarly decreased at all dose levels of MSM: 1 g (16.71 U decrease, 66.86%; P=.03), 3 g (18.57 U decrease, 55.71%; P=.04), and 6 g (12.95 U decrease, 46.10%; P=.04) from screening to V3
PMID 30497995 · one of two readings recorded this
VAS rhinorrhea, V1 to V3
decreases, p = 0.04
Rhinorrhea symptoms were similarly decreased at all dose levels of MSM: 1 g (16.71 U decrease, 66.86%; P=.03), 3 g (18.57 U decrease, 55.71%; P=.04), and 6 g (12.95 U decrease, 46.10%; P=.04) from screening to V3
PMID 30497995 · one of two readings recorded this
VAS rhinorrhea, V1 to V3
decreases, p = 0.04
Rhinorrhea symptoms were similarly decreased at all dose levels of MSM: 1 g (16.71 U decrease, 66.86%; P=.03), 3 g (18.57 U decrease, 55.71%; P=.04), and 6 g (12.95 U decrease, 46.10%; P=.04) from screening to V3
PMID 30497995 · one of two readings recorded this
VAS sneezing, V1 to V2
increases, p = 0.002
sneezing was increased significantly after administration of allergen (12.46 U increase, 72.02%; P=.002; Figure 2)
PMID 30497995 · one of two readings recorded this
VAS sneezing, V1 to V3
decreases, p = 0.04
Sneezing was affected only by the MSM 3-g dose, with a decrease of 14.76 U (63.92%; P=.04) from screening to day 14
PMID 30497995 · one of two readings recorded this
VAS watery eyes, V1 to V2
decreases, p = 0.001
watery eyes (11.27 U decrease, 53.18%; P=.001)
PMID 30497995 · one of two readings recorded this
VAS watery eyes, V1 to V3
decreases, p = 0.02
watery eyes were significantly relieved only at low doses of MSM: 1 g (13.67 U decrease, 72.66%; P=.02), 3 g (20.00 U decrease, 79.25%; P=.01), and 6 g (8.67 U decrease, 44.39%; P=.09) from screening to day 14
PMID 30497995 · one of two readings recorded this
VAS watery eyes, V1 to V3
decreases, p = 0.01
watery eyes were significantly relieved only at low doses of MSM: 1 g (13.67 U decrease, 72.66%; P=.02), 3 g (20.00 U decrease, 79.25%; P=.01), and 6 g (8.67 U decrease, 44.39%; P=.09) from screening to day 14
PMID 30497995 · one of two readings recorded this
VAS watery eyes, V1 to V3
decreases, p = 0.09
watery eyes were significantly relieved only at low doses of MSM: 1 g (13.67 U decrease, 72.66%; P=.02), 3 g (20.00 U decrease, 79.25%; P=.01), and 6 g (8.67 U decrease, 44.39%; P=.09) from screening to day 14
PMID 30497995 · one of two readings recorded this
creatinine
no effect
MSM has no effects on WBC, platelets, Hb, total bilirubin, AST, ALT, creatinine weight, DBP, or SBP in this study
PMID 31331587 · one of two readings recorded this
hemoglobin
no effect
MSM has no effects on WBC, platelets, Hb, total bilirubin, AST, ALT, creatinine weight, DBP, or SBP in this study
PMID 31331587 · one of two readings recorded this
alanine aminotransferase (ALT)
no effect
MSM has no effects on WBC, platelets, Hb, total bilirubin, AST, ALT, creatinine weight, DBP, or SBP in this study
PMID 31331587 · one of two readings recorded this
aspartate aminotransferase (AST)
no effect
MSM has no effects on WBC, platelets, Hb, total bilirubin, AST, ALT, creatinine weight, DBP, or SBP in this study
PMID 31331587 · one of two readings recorded this
body weight
no effect
MSM has no effects on WBC, platelets, Hb, total bilirubin, AST, ALT, creatinine weight, DBP, or SBP in this study
PMID 31331587 · one of two readings recorded this
diastolic blood pressure
no effect
MSM has no effects on WBC, platelets, Hb, total bilirubin, AST, ALT, creatinine weight, DBP, or SBP in this study
PMID 31331587 · one of two readings recorded this
platelet count
no effect
MSM has no effects on WBC, platelets, Hb, total bilirubin, AST, ALT, creatinine weight, DBP, or SBP in this study
PMID 31331587 · one of two readings recorded this
safety laboratory and physiologic values (WBC, platelets, hemoglobin, glucose, total bilirubin, ALT, AST, creatinine, weight, DBP, SBP) at 16 weeks of 6 g/day MSM versus placebo
no effect
Not recorded as a finding: the supporting sentence never names the compound
Analysis of outcome measures showed no significant difference between MSM and placebo (p < 0.05) safety values.
PMID 31331587 · one of two readings recorded this
safety laboratory and physiologic values (WBC, platelets, hemoglobin, glucose, total bilirubin, ALT, AST, creatinine, weight, diastolic and systolic blood pressure) on 6 g/day MSM versus placebo for 16 weeks
no effect
Not recorded as a finding: the supporting sentence never names the compound
Analysis of outcome measures showed no significant difference between MSM and placebo (p < 0.05) safety values.
PMID 31331587 · one of two readings recorded this
systolic blood pressure
no effect
MSM has no effects on WBC, platelets, Hb, total bilirubin, AST, ALT, creatinine weight, DBP, or SBP in this study
PMID 31331587 · one of two readings recorded this
total bilirubin
no effect
MSM has no effects on WBC, platelets, Hb, total bilirubin, AST, ALT, creatinine weight, DBP, or SBP in this study
PMID 31331587 · one of two readings recorded this
white blood cell count
no effect
MSM has no effects on WBC, platelets, Hb, total bilirubin, AST, ALT, creatinine weight, DBP, or SBP in this study
PMID 31331587 · one of two readings recorded this
fasting blood glucose
no effect
no differences were found at baseline, or any time point for fasting blood glucose, insulin, HOMA index, total cholesterol, LDL, VLDL, or triglycerides
PMID 34684621 · one of two readings recorded this
HOMA-IR
no effect
no differences were found at baseline, or any time point for fasting blood glucose, insulin, HOMA index, total cholesterol, LDL, VLDL, or triglycerides
PMID 34684621 · one of two readings recorded this
LDL cholesterol
no effect
no differences were found at baseline, or any time point for fasting blood glucose, insulin, HOMA index, total cholesterol, LDL, VLDL, or triglycerides
PMID 34684621 · one of two readings recorded this
triglycerides
no effect
no differences were found at baseline, or any time point for fasting blood glucose, insulin, HOMA index, total cholesterol, LDL, VLDL, or triglycerides
PMID 34684621 · one of two readings recorded this
total antioxidant capacity
no effect
The total antioxidant capacity of the serum was not different between the MSM and placebo group
PMID 34684621 · one of two readings recorded this
TNF-alpha
no effect
No differences were detected for TNFα or IL-6
PMID 34684621 · one of two readings recorded this
IL-6
no effect
No differences were detected for TNFα or IL-6
PMID 34684621 · one of two readings recorded this
anthropometric measures
no effect
no differences were found between groups for any of the anthropometric measures, blood pressure, resting metabolic rate, or respiratory exchange ratio during treatment
PMID 34684621 · one of two readings recorded this
baseline fat intake
increases
fat intake was higher in the group receiving MSM
PMID 34684621 · one of two readings recorded this
blood pressure
no effect
no differences were found between groups for any of the anthropometric measures, blood pressure, resting metabolic rate, or respiratory exchange ratio during treatment
PMID 34684621 · one of two readings recorded this
correlation of serum MSM concentration with outcome measures
no effect
No significant correlations were found between serum MSM concentration and any outcome measure
PMID 34684621 · one of two readings recorded this
CRP across time, MSM group
no effect
CRP was unchanged in the MSM group
PMID 34684621 · one of two readings recorded this
CRP, MSM versus placebo at week 16
decreases, p = 0.04
CRP was significantly lower in MSM compared to placebo at week 16 (p = 0.04)
PMID 34684621 · one of two readings recorded this
CRP, placebo group, week 16 versus week 4
increases, p = 0.021
CRP increased across time in the placebo group, with significant differences found from week 4 compared to week 8 and 16 (p = 0.039, p = 0.021)
PMID 34684621 · one of two readings recorded this
CRP, placebo group, week 8 versus week 4
increases, p = 0.039
CRP increased across time in the placebo group, with significant differences found from week 4 compared to week 8 and 16 (p = 0.039, p = 0.021)
PMID 34684621 · one of two readings recorded this
fasting glucose, insulin, HOMA index, total cholesterol, LDL, VLDL, triglycerides, between groups at any timepoint
no effect
Not recorded as a finding: lumped agentless sentence that never names MSM or placebo
Additionally, no differences were found at baseline, or any time point for fasting blood glucose, insulin, HOMA index, total cholesterol, LDL, VLDL, or triglycerides (Table 2).
PMID 34684621 · one of two readings recorded this
fasting insulin
no effect
no differences were found at baseline, or any time point for fasting blood glucose, insulin, HOMA index, total cholesterol, LDL, VLDL, or triglycerides
PMID 34684621 · one of two readings recorded this
HDL cholesterol, between-group comparison (primary finding), LabCorp serum assay
no effect
Not recorded as a finding: sentence names only 'the experimental group' and 'between groups', never MSM or placebo, and the Methods never define that label; the within-group rise from baseline is not a contrast
However, in the experimental group HDL was increased at 8 and 16 weeks compared with baseline (p = 0.008, p = 0.013), although there were no significant differences between groups.
PMID 34684621 · one of two readings recorded this
HDL cholesterol, between-group difference
no effect
in the experimental group HDL was increased at 8 and 16 weeks compared with baseline (p = 0.008, p = 0.013), although there were no significant differences between groups
PMID 34684621 · one of two readings recorded this
HDL cholesterol, between-group, weeks 4 to 16
no effect
Not recorded as a finding: The only sentence is about the experimental group versus its own baseline and says no significant differences between groups without naming MSM or placebo; primary endpoint, so recorded here
However, in the experimental group HDL was increased at 8 and 16 weeks compared with baseline (p = 0.008, p = 0.013), although there were no significant differences between groups.
PMID 34684621 · one of two readings recorded this
HDL cholesterol, change from baseline at 16 weeks
increases, p = 0.013
in the experimental group HDL was increased at 8 and 16 weeks compared with baseline (p = 0.008, p = 0.013), although there were no significant differences between groups
PMID 34684621 · one of two readings recorded this
HDL cholesterol, change from baseline at 8 weeks
increases, p = 0.008
in the experimental group HDL was increased at 8 and 16 weeks compared with baseline (p = 0.008, p = 0.013), although there were no significant differences between groups
PMID 34684621 · one of two readings recorded this
PIIINP
no effect
No differences were found between the groups for PIIINP or PINP
PMID 34684621 · one of two readings recorded this